Fee Schedule Guidelines Outpatient Hospital



Fee Schedule Guideline – Outpatient Hospital January 2024

Notice

The five character numeric codes included in the North Dakota Fee Schedule are obtained from Current Procedural Terminology (CPT[®]), copyright 2023 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physicians. The five character alphanumeric codes included in the North Dakota Fee Schedule are obtained from HCPCS Level II, copyright 2023 by Optum360, LLC. HCPCS Level II codes are maintained jointly by The Centers for Medicare and Medicaid Services (CMS), the Blue Cross and Blue Shield Association (BCBSA), and the Health Insurance Association of America (HIAA).

The responsibility for the content of the North Dakota Fee Schedule is with WSI and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in North Dakota Fee Schedules. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, and are not part of CPT, and the AMA does not recommend their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of North Dakota Fee Schedule should refer to the most current Current Procedural Terminology, which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply. CPT is a registered trademark of the American Medical Association.

The WSI Fee Schedule is not a guarantee of payment. The fact that WSI assigns a procedure or service a HCPCS code and a payment rate does not imply coverage by WSI but indicates the maximum allowable payment for approved services. Services represented are subject to provisions of WSI including: compensability, claim payment logic, applicable medical policy, benefit limitations and exclusions, bundling logic, and licensing scope of practice limitations.

Any changes made to Pricing Methodology are subject to the North Dakota Public Hearing process. WSI reserves the right to implement changes to the Payment Parameters, Billing Requirements, and Reimbursement Procedures as needed. WSI incorporates all applicable changes into the relevant Fee Schedule Guideline at the time of implementation, and communicates these changes in Medical Providers News, available on the WSI website at www.workforcesafety.com/news/medical-providers. WSI reviews and updates all Fee Schedule rates on an annual basis, with additional updates made on a quarterly basis when applicable.

For reference purposes, the sections of the North Dakota Administrative Code (N.D.A.C.) that regulate medical services are **92-01-02-27 through 92-01-02-46**. The complete N.D.A.C. is accessible on the North Dakota Legislative Council <u>website</u>: http://www.legis.nd.gov/agency-rules/north-dakota-administrative-code.

Table of Contents

| Outpatient Hospital Pricing Methodology | 4 |
|--|----|
| Outpatient Hospital Payment Parameters | 7 |
| Outpatient Hospital Billing Requirements | 10 |
| Outpatient Hospital Reimbursement Procedures | 13 |
| Outpatient Hospital APC Descriptions | 14 |
| Outpatient Hospital APC Grouper Returns | 25 |

North Dakota Workforce Safety & Insurance Outpatient Hospital Pricing Methodology

Outpatient Hospital Pricing Methodology outlines the methods used by Workforce Safety and Insurance (WSI) to determine the final rates represented on the Outpatient Hospital Fee Schedule. The Outpatient Hospital Fee Schedule uses the applicable procedure codes and descriptions as defined by the Healthcare Common Procedure Coding System (HCPCS), their respective payment status indicators, and payment amounts. In accordance with <u>North Dakota Administrative Code 92-01-02-29.2</u>, any hospital rendering treatment to a claimant under the jurisdiction of WSI is reimbursed according to the rates assigned in the WSI Fee Schedule. A hospital may access the complete <u>Outpatient Hospital Fee Schedule</u> and other resources referenced within this document by visiting the Medical Provider section of the WSI website: www.workforcesafety.com.

Status Indicators

WSI assigns one of the following status indicators to each HCPCS or APC code within the Outpatient Hospital Fee Schedule:

| HCPCS | APC | Description | Pricing Methodology |
|-------|-----|---|---|
| В | | Code that is not recognized when submitted on a UB-04 with bill types 12x, 13x, or 14x | Service is not payable under the Outpatient Hospital Fee Schedule. WSI may recognize an alternate code. |
| С | | Inpatient procedure | Service is not payable under the Outpatient Hospital Fee Schedule. Pricing is determined under the Inpatient Hospital Fee Schedule. |
| D | D | Discontinued code | Service is not payable. Code was discontinued effective beginning of the calendar year. |
| E | | Code not reportable in an outpatient hospital setting | Service is not payable under the Outpatient Hospital Fee Schedule. |
| F | | Corneal tissue acquisition, Hepatitis B vaccine | Service is payable at 85% of the amount billed. |
| G | G | Drug/biological pass-through; brachytherapy sources | Service is payable at the rate published on the Outpatient Hospital Fee Schedule. |
| н | н | Device pass-through categories | Service is payable at 120% of the invoice cost, when provided in conjunction with a covered Outpatient Hospital procedure. |
| J | J | Service that is payable under a comprehensive APC | Service is payable at the APC rate published on the Outpatient Hospital Fee Schedule, which may be complexity adjusted for secondary and add-on codes. APC payment includes all services provided in an outpatient encounter with the exception of those services with status indicators of F, G or H. |
| J2 | | Service that is payable when performed separate from a comprehensive APC | Service is payable at the rate published on the Outpatient Hospital Fee Schedule when performed separate from a comprehensive APC. |
| к | к | Non pass-through drugs and biologicals; therapeutic radiopharmaceutical agents; blood and blood products | Service is payable at the rate published on the Outpatient Hospital Fee Schedule. |
| N | | Packaged code | Service is not separately payable. Payment is packaged into the payment for another service. |

| HCPCS | APC | Description | Pricing Methodology |
|-------|-----|---|--|
| Q1 | | Service that is packaged when billed with another service that has an J, S, or T status indicator | Service is payable at the rate published on the Outpatient Hospital Fee Schedule when performed separate from a service assigned a status indicator of J, S, or T |
| Q2 | | Service that is packaged when billed with another service that has a J or T status indicator | Service is payable at the rate published on the Outpatient Hospital Fee Schedule when performed separate from a service assigned a status indicator of J or T |
| Q3 | | Service that is packaged when paid through a Composite APC | Service is payable at the rate published on the Outpatient Hospital Fee Schedule when performed separate from a Composite APC. |
| Q4 | | Laboratory service that is packaged when billed with any other payable service | Service is payable at the rate published on the Clinical Laboratory Fee Schedule when performed separate from any other payable service. |
| S | S | Procedure or service, multiple procedure reductions not applied | Service is payable at the rate published on the Outpatient Hospital Fee Schedule without multiple procedure reductions applied. |
| т | т | Procedure or service, multiple procedure reductions applied | Service is payable at the rate published on the Outpatient Hospital Fee Schedule with multiple procedure reductions applied. |
| Y | | Non-implantable durable medical equipment | Service is not payable under the Outpatient Hospital Fee Schedule. Service may be payable under another WSI Fee Schedule. Submit charges on a CMS-1500. |
| Z | | Service that is payable under another WSI Fee Schedule | Service is payable in the outpatient setting; however, pricing is determined under the applicable WSI Fee Schedule. |

Calculation of the Reimbursement Rate

For HCPCS/APC codes assigned a status indicator of "G", "J", "J2" "K", "Q1", "Q2", "Q3", "S", or "T", WSI applies the following formula to determine the maximum allowable reimbursement rate:

HCPCS/ APC Weight X WSI Conversion Factor = Reimbursement Rate

For 2024, the Conversion Factor is \$174.93.

The HCPCS/APC weight is the Medicare weight as indicated in the listing of HCPCS codes and APCs in the final OPPS rule published in the Federal Register each year (commonly known as "Addendums A & B"). WSI calculates the conversion factor based on the prior year's conversion factor times the Hospital Market Basket increase published by The Centers for Medicare and Medicaid Services (CMS) in the Outpatient Prospective Payment System (OPPS) final rule.

- Where Addendums A & B contain a HCPCS/APC code with a payment amount but no weight, WSI computes the weight by taking the Medicare payment amount divided by the Medicare conversion factor.
- Where Addendums A & B contain a payable HCPCS/APC code with no payment amount or weight (i.e., pass through devices paid at cost), WSI payment is payment based on the invoice cost plus 20%. WSI identifies these services with an "H" status indicator.

Annual Updates

WSI updates the Outpatient Hospital Fee Schedule annually based on the Hospital Market Basket increases and HCPCS/APC weights published by CMS. Any delay by CMS in publishing the Hospital Market Basket increase, in updating its weights, or both, will cause a corresponding delay in the update of the WSI conversion factor and weights. WSI also incorporates the quarterly updates published by CMS into the Outpatient Hospital Fee Schedule.

Limitations of the Outpatient Hospital Fee Schedule

The payment rates listed on the Outpatient Hospital Fee Schedule indicate the allowable payment for approved services only. The fact that a procedure or service is assigned a HCPCS code and a payment rate does not imply coverage by WSI but indicates the allowable payment for approved services. The final payment rate may be impacted by the payment parameters and billing requirements enforced by WSI. A hospital is encouraged to carefully review WSI's Payment Parameters, Billing Requirements, and Reimbursement Procedures to avoid unneccesary delays and denials of payment.

North Dakota Workforce Safety & Insurance Outpatient Hospital Payment Parameters

Outpatient Hospital Payment Parameters outline the rules for payment adopted by WSI. While WSI has adopted many of Medicare's rules for payment, WSI has developed a set of unique rules that are applied to the final payment of approved services. The complete payment parameters enforced by WSI are as follows:

Advanced Beneficiary Notice (ABN) – A provider may utilize the ABN form to notify an injured employee of the costs associated with a recommended procedure that is: statutorily excluded from coverage, statutorily limited in quantity, deemed by WSI as not medically necessary to treat the work injury. To identify a charge accompanied with a signed ABN, a provider should append modifier GA to each applicable bill line. A provider should then submit the signed ABN along with the bill and medical documentation to WSI.

Authorization – WSI requires prior authorization for most Outpatient Hospital services. A hospital should refer to the <u>Utilization Review Guide</u> for additional information.

Bilateral Surgery Payment (50) – WSI utilizes Medicare's bilateral surgery payment adjustments for services assigned a status indicator "T" when billed with Modifier 50. WSI issues payment for the primary bilateral procedure at 150% of the fee schedule rate. If a bilateral procedure is a secondary procedure, the service is reimbursable at 75% of the fee schedule rate.

WSI does not apply bilateral procedure discounting to those procedures identified with status indicator "S".

Distinct Procedural Services (59) – WSI applies the standard Outpatient Hospital payment packaging policies to distinct procedural services.

Discontinued Procedure Discounting (73, 74, 52) – For services billed with modifier 73, if the procedure code is the highest weighted code, WSI prices it at 50% of the Outpatient Hospital Fee Schedule rate. If the procedure code is not the highest weighted code, WSI prices it at 25% of the Outpatient Hospital Fee Schedule rate.

WSI prices procedures billed with modifiers 74 and 52 as if no modifier were present (i.e., with normal multiple procedure discounting).

Modifier Usage – WSI does not require, but does permit, the use of all Medicare OPPS required modifiers.

Multiple Procedure Discounting – WSI applies multiple procedure discounting to codes identified with status indicator "T". If the procedure code is the highest weighted code, WSI prices it at 100% of the Outpatient Hospital Fee Schedule rate. If the procedure code is not the highest weighted code, WSI prices it at 50% of the Outpatient Hospital Fee Schedule rate.

WSI does not apply multiple procedure discounting to those procedures identified with status indicator "S".

NCCI Edits – WSI incorporates all applicable NCCI edits.

New Codes with no Payment – WSI pays for new codes that Medicare has not yet assigned a payment for (either through the APC payment system or through the Medicare Part B Fee Schedules) at 85% of billed charges.

Observation Services – A hospital must bill observation services in hourly increments with HCPCS code G0378. WSI allows observation stays of 48 hours or less.

Outlier Payments- WSI does not incorporate outlier provisions into the Outpatient Hospital Fee Schedule

Packaged Drug Offsets – WSI does not incorporate Medicare's "Threshold Packaged" and "Policy Packaged" drug offsets.

Pass-Through Devices – WSI incorporates Medicare's pass-through device offset methodology. WSI uses the offset percentages published by Medicare when determining the appropriate amounts for those procedures involving pass-through devices.

Payment Packaging – WSI has adopted Medicare's Outpatient Hospital payment packaging policies as follows:

Unconditional Packaging – WSI assigns a status indicator of "N" to unconditionally packaged services. WSI includes the reimbursement of these services in the payment for the primary procedure(s).

Conditional Packaging – WSI assigns a status indicator of "Q1", "Q2", "Q3", or "Q4" to conditionally packaged services. Reimbursement for these services is dependent upon whether another qualifying service was provided during any given outpatient hospital service, as described by each status indicator's description. WSI applies additional conditional packaging as follows:

- When multiple Q1 services are performed separate from another S or T service, only the highest weighted Q1 service is payable. WSI packages the payment for all other Q1 services.
- When multiple Q2 services are performed separate from another T service, only the highest weighted Q2 service is payable. WSI packages the payment for all other Q2 services.
- When Q1 and Q2 services are performed separate from another S or T service, only the highest weighted Q1 or Q2 service is payable. WSI packages the payment for all other Q1 and Q2 services.
- Q1 and Q2 services are not separately payable when performed with other services that qualify for a composite APC payment.

Composite APC – WSI packages certain groups of similar, related services into a single composite payment.

Comprehensive APC – WSI assigns a status indicator of "J" to services that qualify for a comprehensive payment. Reimbursement for a comprehensive service incorporates payment for other services provided during an outpatient hospital encounter. WSI does not package services assigned a status indicator of "F", "G", or "H" into a comprehensive APC payment.

Prospective Payments – WSI pays outpatient hospital services at the rate indicated on the WSI Outpatient Hospital Fee Schedule, regardless of the billed amount, except for codes assigned a status indicator of 'Z'. For codes assigned a status indicator of 'Z', WSI pays the "lesser of" the billed charge or the Fee Schedule amount.

Provider-Based Clinics – WSI does not recognize clinics as provider-based. A provider must bill services of a type typically performed in a physician's office on a CMS 1500 claim form, with the following exceptions:

- An Urgent Care center that is located next to an Emergency Department, which shares a common registration or triage area with the Emergency Department and bills a facility fee to all payers. Facility charges for these services can be billed with Revenue Code 456 or 516
- A Pain Clinic located within the hospital's main building. Providers may bill facility charges for these services with Revenue Code 511.

Repeat Procedure Modifiers (76,77,78,79) – Procedures with modifiers 76, 77, 78, or 79 are not subject to multiple procedure discounting and are paid at the Outpatient Hospital fee schedule amount. These modifiers represent a return to the operating room or treatment area and indicate the reported procedures were not completed during the same operative session.

Replacement Device Offsets – WSI incorporates Medicare's device offset methodology for those instances where replacement devices are provided at either no cost by the manufacturer or where the hospital received a credit of 50 percent or more of the estimated cost of the new replacement device. WSI uses the offset percentages published by Medicare when determining the appropriate payment reduction cap for those procedures involving replacement devices. Hospitals must bill using value code FD and the amount of the device credit received when a device is replaced at either no cost or at an amount that is 50 percent or more of the cost of the original device.

Wage Adjustments – WSI does not wage adjust the conversion factor.

North Dakota Workforce Safety & Insurance Outpatient Hospital Billing Requirements

Outpatient Hospital Billing Requirements outline the rules for billing adopted by WSI. WSI returns or denies inappropriately submitted bills. WSI notifies a hospital of inappropriately submitted bills via a return letter or remittance advice. A hospital must correct any returned bills prior to resubmission.

Bilateral Surgical Procedures – A hospital is required to bill a bilateral procedure as a single line item with the bilateral procedure modifier (50) appended to the line item.

Bill Form – A hospital must submit a medical bill for outpatient services on a UB-04 form or via EDI. With the exception of recurring services, such as therapy, a provider should submit charges for separate encounters on distinct bill forms in order to prevent excessive payment packaging.

Bill Form Submission – WSI offers the following options for bill submission:

Electronic Billing – A provider submitting more than 50 bills per year to WSI must send charges electronically through Carisk Intelligent Clearinghouse. This option allows for the electronic submission of professional (837p) and institutional (837i) charges along with supporting medical documentation. Contact Carisk at 888-238-4792 for additional information.

Paper Billing – A provider submitting less than 50 bills per year to WSI may send charges in red and white paper format with supporting medical documentation at the following address:

Workforce Safety & Insurance PO Box 5585 Bismarck, ND 58506

Coding – A hospital is required to bill using only current and appropriate CPT and HCPCS Level II codes for medicine services.

Discontinued Procedures – When an operative session is terminated either prior to or subsequent of the administration of anesthesia (modifiers 73 or 74), only the primary planned procedure(s) may be reported on the claim. WSI reviews any claim with modifier 73 or 74 containing more than 1 "T" status procedure code, and may request records to substantiate multiple primary planned procedures.

Durable Medical Equipment – A hospital should bill for separately payable DME and supply items, not provided as part of an outpatient encounter, on a CMS-1500 claim form in order for WSI to review for reimbursement based on the WSI DME fee schedule.

Fitness Center Services – When WSI approves an independent exercise program, facilities may bill for the fitness center services using WSI-specific code W0555 on a CMS 1500, or by submitting an invoice for the charges.

Inpatient Hospital vs. Outpatient Hospital Classification – WSI requires a hospital to bill all patient stays of 24 hours or less as outpatient stays unless the surgical procedure performed has a status indicator of "C". A hospital must bill all patient stays for surgical services where the HCPCS code for the surgery has a status indicator of "C" (inpatient only) as inpatient, regardless of the length of the stay.

Line-Item Billing – WSI requires line item date of service billing for all lines, with the exception of observation services.

Medical Documentation – A hospital must submit medical documentation to support all billed charges. WSI's <u>Documentation Policies</u> are available for detailed information on documentation requirements.

Medical Necessity – A provider is required to bill using the same medical necessity guidelines used for Medicare.

Multiple Encounters – A hospital may combine multiple outpatient hospital encounters on the same day (i.e., the patient leaves the hospital and returns later in the day for other services) into one bill for that date of service, or each encounter may be billed on separate claims. However, a hospital must bill all services occurring during an individual encounter with a hospital on a single claim.

Multiple Surgical Procedures – A hospital must bill multiple surgical procedures on subsequent lines.

National Provider Identification (NPI) – WSI requires entities who are eligible for NPI to be registered with National Plan & Provider Enumeration System. When applicable, WSI requires a hospital to include the NPI at both the rendering provider and billing provider levels.

Observation Services – A hospital must use revenue code 762 and HCPCS code G0378 to report observation services. A hospital should bill observation services in hourly increments to ensure proper payment.

Orthotics and Prosthetics – A hospital may bill for orthotics (HCPCS codes L0000-L4999) and prosthetics (HCPCS codes L5000-L9999) on either the UB-04 claim form with revenue code 274 or on the CMS 1500 claim form. WSI determines the pricing for these services based on the existing WSI DME fee schedule.

Pain Clinics – WSI allows the reimbursement of a facility fee for a pain clinic located within a hospital. A hospital must bill this fee with Revenue Code 511 and an appropriate HCPCS code.

Phase III Cardiac Rehab Services – A hospital must submit charges for phase III cardiac rehab services separate from all other services, using revenue code 994 to ensure proper reimbursement.

Professional Fees – A hospital must bill all professional services described by revenue codes 96X, 97X, and 98X on the CMS 1500 claim form.

Rural Health Clinic – WSI does not reimburse for rural health clinic charges submitted on the UB-04. A rural health clinic must submit charges on the CMS-1500.

Services without Valid HCPC Codes – A hospital may combine revenue codes for which there are no valid HCPCS codes into one line.

Take-Home Drugs – WSI does not separately reimburse take-home drugs and packages the payment for this service into the main procedure(s).

Timely Filing – A hospital must submit bills to WSI within 365 days of the date of service.

Units of Service – WSI requires all units of service match the description of the HCPCS code. A hospital must bill surgical HCPCS codes with units that equal the number of times the procedure was performed, as indicated by the code's description.

Urgent Care Centers – WSI allows for the reimbursement of a facility fee for an urgent care centers when the following criteria are met:

- Urgent care center is located next to the emergency department
- Urgent care center shares a registration or triage area with the emergency department
- The hospital bills a facility fee for the urgent care center to all payers

A hospital must bill this facility fee with Revenue Code 456 or 516 accompanied by an appropriate HCPCs or CPT code.

North Dakota Workforce Safety & Insurance Outpatient Hospital Reimbursement Procedures

Outpatient Hospital Reimbursement Procedures outline how WSI communicates bill processing information and issues payment to a hospital. In addition, it outlines WSI requirements for reimbursement. A provider is encouraged to follow WSI Reimbursement Procedures to prevent delays in the payment processing of medical charges submitted to WSI.

Provider Registration – Prior to reimbursement for treatment, a provider is required to register the applicable Billing NPIs with WSI by completing the <u>Medical Provider Payee Registration</u> form. For additional information, visit the <u>Provider Registration</u> section of WSI's website.

Payment Address – WSI issues payment to the Pay-to Address registered on the <u>Medical</u> <u>Provider Payee Registration</u> form, regardless of the address submitted on the bill form. To update a payment address, a provider must resubmit the registration form for each applicable Billing NPI.

Remittance Advice – WSI issues remittance advices for processed medical bills each Friday. The remittance advice includes important information about a medical charge, including: patient name, date of service, procedure billed, billed amount, paid amount, and remittance advice reason codes. A provider should refer to the <u>How to Read the WSI Remittance Advice</u> document for assistance with interpretation of the remittance advice. This reference includes a sample remittance advice, along with definitions for significant fields within the remittance advice. Contact customer service at 1-800-777-5033 with questions or to obtain a duplicate remittance advice.

Reason Codes – The <u>WSI Remittance Advice Reason Codes</u> document provides a comprehensive listing and description of the reason codes utilized by WSI. Each reason code identifies a cause for the adjudication of a medical charge and specifies whether a provider may bill a patient. When a reason code specifies a provider may bill a patient, WSI sends a "Notice of Non-Payment" letter to the patient informing them of their responsibility for the charge. In accordance with <u>North Dakota Administrative Code 92-01-02-45.1</u>, if a reason code does not state that a provider may bill a patient, the provider cannot bill the charge for the reduced or denied service to the patient, the employer, or another insurer.

Bill Status Inquiries – Bill status information is available 24/7 via myWSI. The Provider Bill Status application permits a registered user to view bill receipt status and processing details as well as export results. For access, a practice must submit a <u>myWSI Portal Registration</u> (<u>M14</u>) form for each group/billing NPI. With the availability of this resource, a provider or their TPA will not need to contact WSI via phone or email to inquire on the status of a billed charge.

Overpayments – When an overpayment occurs on a medical bill, WSI will notify the provider of the overpayment in a letter. WSI allows 30 days from the date of the letter for a provider to issue the requested refund. If a provider does not issue the refund within 30 days of the date of the letter, WSI will withhold the overpayment from future payments.

Medical Services Disputes – <u>North Dakota Administrative Code 92-01-02-46</u> provides the procedures followed for managed care disputes. A provider who wishes to dispute a denial or reduction of a service charge must submit the <u>Medical Bill Appeal (M6)</u> form, along with supporting documentation, within 30 days of the remittance advice issue date. WSI will not address a provider dispute submitted without the M6 form.

| APC | Description |
|------|------------------------------|
| 0701 | Sr89 strontium |
| 0702 | Inj, balfaxar, per i.u |
| 0703 | Inj daxibotulinumtoxinA-lanm |
| 0704 | Inj, aflibercept hd, 1 mg |
| 0705 | Inj, avacincaptad peg 0.1 mg |
| 0706 | Inj talquetamab-tgvs 0.25 mg |
| 0707 | Cantharidin top, applicator |
| 0708 | Inj, elranatamab-bcmm, 1 mg |
| 0709 | Flortaucipir inj 1 millicuri |
| 0710 | Inj velmanase alfa-tycv 1 mg |
| 0711 | Inj, artesunate, 1mg |
| 0713 | Inj roctavian ml 2x10^13vc g |
| 0714 | Inj delandistrogene mox rokl |
| 0715 | Pegunigalsidase alfa-iwxj |
| 0716 | Vyjuvek 5x10^9pfu/ml, 0.1 ml |
| 0717 | Instill adstiladrin, tx dose |
| 0718 | Inj, carmustine (accord) |
| 0719 | Inj cyclophos dr.reddy's 5mg |
| 0720 | Inj glofitamab gxbm, 2.5 mg |
| 0721 | Inj ronzanolixizum-noli 1 mg |
| 0722 | Dexmedetomidine film, 1 mcg |
| 0723 | Inj efgart-alfa 2mg hya-qvfc |
| 0724 | Inj. olanzapine, 0.5mg |
| 0726 | Dexrazoxane HCI injection |
| 0731 | Sargramostim injection |
| 0736 | Amphotericin b liposome inj |
| 0738 | Rasburicase |
| 0752 | Dactinomycin injection |
| 0759 | Naltrexone, depot form |
| 0800 | Leuprolide acetate |
| 0802 | Etoposide oral |
| 0807 | Aldesleukin injection |
| 0810 | Goserelin acetate implant |
| 0812 | Carmustine injection |
| 0820 | Daunorubicin injection |
| 0825 | Nelarabine injection |
| 0827 | Floxuridine injection |
| 0836 | Interferon alfa-2b inj |
| 0840 | Inj melpha hydroch nos 50 mg |
| 0843 | Pegaspargase injection |
| 0844 | Pentostatin injection |
| 0850 | Streptozocin injection |
| 0851 | Thiotepa injection |
| 0856 | Porfimer sodium injection |
| 0858 | Inj cladribine |

| APC | Description |
|------|------------------------------|
| | |
| 0864 | Mitoxantrone hydrochl |
| 0874 | Synvisc or synvisc-one |
| 0875 | Euflexxa inj per dose |
| 0877 | Orthovisc inj per dose |
| 0887 | Azathioprine parenteral |
| 0890 | Lymphocyte immune globulin |
| 0901 | Alpha 1 proteinase inhibitor |
| 0902 | Injection,onabotulinumtoxinA |
| 0903 | Cytomegalovirus imm IV /vial |
| 0925 | Factor viii |
| 0927 | Factor viii recombinant |
| 0928 | Factor ix complex |
| 0929 | Anti-inhibitor |
| 0931 | Factor IX non-recombinant |
| 0932 | Factor ix recombinant nos |
| 0943 | Octagam injection |
| 0944 | Gammagard liquid injection |
| 0946 | Hepagam b im injection |
| 0947 | Flebogamma injection |
| 0948 | Gamunex-C/Gammaked |
| 0961 | Albumin (human),5%, 50ml |
| 0963 | Albumin (human), 5%, 250 ml |
| 0964 | Albumin (human), 25%, 20 ml |
| 0965 | Albumin (human), 25%, 50ml |
| 1015 | Injection glatiramer acetate |
| 1064 | I131 iodide cap, rx |
| 1083 | Adalimumab injection |
| 1138 | Hepagam b intravenous, inj |
| 1139 | Protein c concentrate |
| 1142 | Supprelin LA implant |
| 1150 | I131 iodide sol, rx |
| 1168 | Inj, temsirolimus |
| 1178 | Busulfan injection |
| 1203 | Verteporfin injection |
| 1207 | Octreotide injection, depot |
| 1213 | Antihemophilic viii/vwf comp |
| 1214 | Inj IVIG privigen 500 mg |
| 1232 | Mitomycin injection |
| 1233 | Inj, vasopressin, 1 unit |
| 1234 | Inj vasopressin (am reg) 1 u |
| 1235 | Valrubicin injection |
| 1236 | Inj levoleucovorin nos 0.5mg |
| 1237 | Inj iron dextran |
| 1238 | Topotecan oral |
| 1263 | Antithrombin iii injection |
| | · |

| APC | Description |
|------|---------------------------------------|
| 1268 | Xyntha inj |
| 1274 | Edetate calcium disodium inj |
| 1281 | Bevacizumab injection |
| 1289 | AbobotulinumtoxinA |
| 1295 | Sm 153 lexidronam |
| 1296 | Degarelix injection |
| 1297 | Ferumoxytol, non-esrd |
| 1311 | Canakinumab injection |
| 1312 | Hizentra injection |
| 1327 | Imiglucerase injection |
| 1331 | Olanzapine long-acting inj |
| 1340 | Collagenase, clost hist inj |
| 1341 | Amobarbital 125 MG inj |
| 1352 | Wilate injection |
| 1353 | Belimumab injection |
| 1408 | Cyclophosphamide 100 MG inj |
| 1413 | Lumizyme injection |
| 1415 | Glassia injection |
| 1416 | Factor xiii anti-hem factor |
| 1417 | Gel-one |
| 1420 | Aflibercept injection |
| 1421 | Imported lipodox inj |
| 1426 | Eribulin mesylate injection |
| 1431 | Centruroides immune f(ab) |
| 1433 | Calcitonin salmon injection |
| 1440 | Inj desmopressin acetate |
| 1442 | Non-HEU TC-99M add-on/dose |
| 1443 | Icatibant injection |
| 1446 | Visualization adjunct |
| 1458 | Phentolaine mesylate inj |
| 1466 | Inj, vincristine sul lip 1mg |
| 1467 | Factor ix recombinan rixubis |
| 1468 | Inj Aripiprazole Ext Rel 1mg |
| 1469 | Inj filgrastim excl biosimil |
| 1471 | Injection, Pertuzumab, 1 mg |
| 1472 | Inj beta interferon im 1 mcg |
| 1474 | Certolizumab pegol inj 1mg |
| 1475 | Golimumab for iv use 1mg |
| 1476 | Obinutuzumab inj |
| 1478 | Inj human fibrinogen con nos |
| 1480 | Elosulfase alfa, injection |
| 1482 | Darbepoetin alfa, esrd use |
| 1485 | Ferumoxytol, esrd use |
| 1486 | Factor ix fc fusion recomb |
| 1488 | Injection, ramucirumab |
| 1489 | Injection, vedolizumab |
| 1490 | Inj pembrolizumab |
| 1491 | New Technology - Level 1A (\$0-\$10) |
| 1492 | New Technology - Level 1B (\$11-\$20) |

| ADC | Description |
|------------|---|
| APC | Description |
| 1493 | New Technology - Level 1C (\$21-\$30) |
| 1494 | New Technology - Level 1D (\$31-\$40) |
| 1495 | New Technology - Level 1E (\$41-\$50) |
| 1496 | New Technology - Level 1A (\$0-\$10) |
| 1497 | New Technology - Level 1B (\$11-\$20) |
| 1498 | New Technology - Level 1C (\$21-\$30) |
| 1499 | New Technology - Level 1D (\$31-\$40) |
| 1500 | New Technology - Level 1E (\$41-\$50) |
| 1502 | New Technology - Level 2 (\$51 - \$100) |
| 1503 | New Technology - Level 3 (\$101 - \$200) |
| 1504 | New Technology - Level 4 (\$201 - \$300) |
| 1505 | New Technology - Level 5 (\$301 - \$400) |
| 1506 | New Technology - Level 6 (\$401 - \$500) |
| 1507 | New Technology - Level 7 (\$501 - \$600) |
| 1508 | New Technology - Level 8 (\$601 - \$700) |
| 1509 | New Technology - Level 9 (\$701 - \$800) |
| 1510 | New Technology - Level 10 (\$801 - \$900) |
| 1511 | New Technology - Level 11 (\$901 - \$1000) |
| 1512 | New Technology - Level 12 (\$1001 - \$1100) |
| 1513 | New Technology - Level 13 (\$1101 - \$1200) |
| 1514 | New Technology - Level 14 (\$1201- \$1300) |
| 1515 | New Technology - Level 15 (\$1301 - \$1400) |
| 1516 | New Technology - Level 16 (\$1401 - \$1500) |
| 1517 | New Technology - Level 17 (\$1501-\$1600) |
| 1518 | New Technology - Level 18 (\$1601-\$1700) |
| 1519 | New Technology - Level 19 (\$1701-\$1800) |
| 1520 | New Technology - Level 20 (\$1801-\$1900) |
| 1521 | New Technology - Level 21 (\$1901-\$2000) |
| 1522 | New Technology - Level 22 (\$2001-\$2500) |
| 1523 | New Technology - Level 23 (\$2501-\$3000) |
| 1524 | New Technology - Level 24 (\$3001-\$3500) |
| 1525 | New Technology - Level 25 (\$3501-\$4000) |
| 1526 | New Technology - Level 26 (\$4001-\$4500) |
| 1527 | New Technology - Level 27 (\$4501-\$5000) |
| 1528 | New Technology - Level 28 (\$5001-\$5500) |
| 1529 | New Technology - Level 29 (\$5501-\$6000) |
| 1530 | New Technology - Level 30 (\$6001-\$6500) |
| 1531 | New Technology - Level 31 (\$6501-\$7000) |
| 1532 | New Technology - Level 32 (\$7001-\$7500) |
| 1533 | New Technology - Level 33 (\$7501-\$8000) |
| 1534 | New Technology - Level 34 (\$8001-\$8500) |
| 1535 | New Technology - Level 35 (\$8501-\$9000) |
| 1536 | New Technology - Level 36 (\$9001-\$9500) |
| 1537 | New Technology - Level 37 (\$9501-\$10000) |
| 1539 | New Technology - Level 2 (\$51 - \$100) |
| 1540 | New Technology - Level 3 (\$101 - \$200) |
| 1541 | New Technology - Level 4 (\$201 - \$300) |
| 1542 | New Technology - Level 5 (\$301 - \$400) |
| 1543 | New Technology - Level 6 (\$401 - \$500) |

| APC | Description |
|--------------|--|
| 1544 | New Technology - Level 7 (\$501 - \$600) |
| 1545 | New Technology - Level 8 (\$601 - \$700) |
| 1546 | New Technology - Level 9 (\$701 - \$800) |
| 1547 | New Technology - Level 10 (\$801 - \$900) |
| 1548 | New Technology - Level 11 (\$901 - \$1000) |
| 1549 | New Technology - Level 12 (\$1001 - \$1100) |
| 1550 | New Technology - Level 13 (\$1101 - \$1200) |
| 1551 | New Technology - Level 14 (\$1201- \$1300) |
| 1552 | New Technology - Level 15 (\$1301 - \$1400) |
| 1553 | New Technology - Level 16 (\$1401 - \$1500) |
| 1554 | New Technology - Level 17 (\$1501-\$1600) |
| 1555 | New Technology - Level 18 (\$1601-\$1700) |
| 1556 | |
| 1557 | New Technology - Level 19 (\$1701-\$1800) |
| | New Technology - Level 20 (\$1801-\$1900) |
| 1558 1559 | New Technology - Level 21 (\$1901-\$2000) |
| - | New Technology - Level 22 (\$2001-\$2500) |
| 1560 1561 | New Technology - Level 23 (\$2501-\$3000) |
| | New Technology - Level 24 (\$3001-\$3500) |
| 1562 | New Technology - Level 25 (\$3501-\$4000) |
| 1563 | New Technology - Level 26 (\$4001-\$4500) |
| 1564 | New Technology - Level 27 (\$4501-\$5000) |
| 1565 | New Technology - Level 28 (\$5001-\$5500) |
| 1566 | New Technology - Level 29 (\$5501-\$6000) |
| 1567 | New Technology - Level 30 (\$6001-\$6500) |
| 1568 | New Technology - Level 31 (\$6501-\$7000) |
| 1569 | New Technology - Level 32 (\$7001-\$7500) |
| 1570 | New Technology - Level 33 (\$7501-\$8000) |
| 1571 | New Technology - Level 34 (\$8001-\$8500) |
| 1572 | New Technology - Level 35 (\$8501-\$9000) |
| 1573 | New Technology - Level 36 (\$9001-\$9500) |
| 1574 | New Technology - Level 37 (\$9501-\$10000) |
| 1575 | New Technology - Level 38 (\$10,001-\$15,000) |
| 1576 | New Technology - Level 39 (\$15,001-\$20,000) |
| 1577 | New Technology - Level 40 (\$20,001-\$25,000) |
| 1578 | New Technology - Level 41 (\$25,001-\$30,000) |
| 1579 | New Technology - Level 42 (\$30,001-\$40,000) |
| 1580 | New Technology - Level 43 (\$40,001-\$50,000) |
| 1581 | New Technology - Level 44 (\$50,001-\$60,000) |
| 1582 | New Technology - Level 45 (\$60,001-\$70,000) |
| 1583 | New Technology - Level 46 (\$70,001-\$80,000) |
| 1584 | New Technology - Level 47 (\$80,001-\$90,000) |
| 1585 | New Technology - Level 48 (\$90,001-\$100,000) |
| 1589 | New Technology - Level 38 (\$10,001-\$15,000) |
| 1590 | New Technology - Level 39 (\$15,001-\$20,000) |
| 1591 | New Technology - Level 40 (\$20,001-\$25,000) |
| 1592 | New Technology - Level 41 (\$25,001-\$30,000) |
| 1593 | New Technology - Level 42 (\$30,001-\$40,000) |
| 1594 | New Technology - Level 43 (\$40,001-\$50,000) |
| 1595 | New Technology - Level 44 (\$50,001-\$60,000) |

| APC | Description |
|------|--|
| 1596 | New Technology - Level 45 (\$60,001-\$70,000) |
| 1597 | New Technology - Level 46 (\$70,001-\$80,000) |
| 1598 | New Technology - Level 47 (\$80,001-\$90,000) |
| 1599 | New Technology - Level 48 (\$90,001-\$100,000) |
| 1608 | Etanercept injection |
| 1609 | Rho(D) immune globulin h, sd |
| 1613 | Trastuzumab injection |
| 1630 | Hep b ig, im |
| 1643 | Y90 ibritumomab, rx |
| 1656 | Factor viii fc fusion recomb |
| 1658 | Injection, belinostat, 10mg |
| 1660 | Injection, oritavancin |
| 1662 | Inj tedizolid phosphate |
| 1669 | Erythro lactobionate /500 mg |
| 1670 | Tetanus immune globulin inj |
| 1675 | P32 Na phosphate |
| 1683 | Basiliximab |
| 1685 | Darbepoetin alfa, non-esrd |
| 1686 | Epoetin alfa, non-esid |
| 1687 | Digoxin immune fab (ovine) |
| 1688 | Ethanolamine oleate |
| 1689 | Fomepizole |
| 1690 | Hemin |
| 1694 | Ziconotide injection |
| 1696 | Palifermin injection |
| 1700 | Inj secretin synthetic human |
| 1701 | Treprostinil injection |
| 1704 | Humate-P, inj |
| 1705 | Factor viia recomb novoseven |
| 1710 | Clofarabine injection |
| 1711 | Vantas implant |
| 1712 | Paclitaxel protein bound |
| 1745 | Radium ra223 dichloride ther |
| 1746 | Factor xiii recomb a-subunit |
| 1747 | Monovisc inj per dose |
| 1748 | Inj tbo filgrastim 1 microg |
| 1761 | Rolapitant, oral, 1mg |
| 1809 | Injection, alemtuzumab |
| 1822 | Injection, zarxio |
| 1823 | Injection, dalbavancin |
| 1824 | Ceftaroline fosamil inj |
| 1825 | Ceftazidime and avibactam |
| 1826 | Hyqvia 100mg immuneglobulin |
| 1827 | Factor viii recomb obizur |
| 1829 | Penicillin g benzathine inj |
| 1832 | Dimethyl sulfoxide 50% 50 ml |
| 1836 | Penicillin g procaine inj |
| 1844 | Factor viii pegylated recomb |
| 1846 | Factor viii nuwiq recomb 1iu |
| | |

| APC | Description |
|------|---|
| 1847 | Injection, inflectra |
| 1848 | Artiss fibrin sealant |
| 1849 | Foscarnet sodium injection |
| 1850 | Gamma globulin 1 cc inj |
| 1851 | Gamma globulin > 10 cc inj |
| 1852 | Interferon beta-1a inj |
| 1853 | Minocycline hydrochloride |
| 1854 | Pentobarbital sodium inj |
| 1856 | Factor viii recomb novoeight |
| 1857 | Inj, factor x, (human), 1iu |
| 1859 | Argatroban nonesrd use 1mg |
| 1861 | Inj., bendeka 1 mg |
| 1862 | Gelsyn-3 injection 0.1 mg |
| 1901 | New Technology - Level 49 (\$100,001-\$115,000) |
| 1902 | New Technology - Level 49 (\$100,001-\$115,000) |
| 1903 | New Technology - Level 50 (\$115,001-\$130,000) |
| 1904 | New Technology - Level 50 (\$115,001-\$130,000) |
| 1905 | New Technology - Level 51 (\$130,001-\$145,000) |
| 1906 | New Technology - Level 51 (\$130,001-\$145,000) |
| 1907 | New Technology - Level 52 (\$145,001-\$160,000) |
| 1908 | New Technology - Level 52 (\$145,001-\$160,000) |
| 2024 | Generator, ccm, implant |
| 2025 | Cath, pressure,valve-occlu |
| 2026 | Orth/devic/drug bn/bn,tis/bn |
| 2027 | Probe, robotic, water-jet |
| 2028 | Iris prosthesis |
| 2030 | Gen, neuro, carot sinus baro |
| 2031 | Hemostatic agent, GI, topic |
| 2032 | Intravertebral fx aug impl |
| 2033 | Cath, trans intra litho/coro |
| 2034 | Personalized interbody cage |
| 2035 | Auto cell process sys |
| 2036 | Cardiac monitor sys |
| 2038 | Gen, neuro, clo loop, rechg |
| 2039 | Gen, neuro, imp led, ex cntr |
| 2040 | Endo, single, urinary tract |
| 2041 | Cath, bladed, vasc prep |
| 2042 | Endo, single, pulmonary |
| 2043 | Orth/matrx/bn fill drug-elut |
| 2044 | Ret dev, laser, ivc filter |
| 2045 | Grft, trnsmurl/trnsvens byps |
| 2616 | Brachytx, non-str, Yttrium-90 |
| 2632 | Iodine I-125 sodium iodide |
| 2634 | Brachytx, non-str, HA, I-125 |
| 2635 | Brachytx, non-str, HA, P-103 |
| 2636 | Brachy linear, non-str,P-103 |
| 2638 | Brachytx, stranded, I-125 |
| 2639 | Brachytx, non-stranded,I-125 |
| 2640 | Brachytx, stranded, P-103 |

| APC | Description |
|--------------|---|
| 2641 | Description Brachuty, pop stranded B 103 |
| | Brachytx, non-stranded, P-103 |
| 2642 | Brachytx, stranded, C-131 |
| 2643 | Brachytx, non-stranded,C-131 |
| 2645 | Brachytx, non-str, Gold-198 |
| 2646 | Brachytx, non-str, HDR Ir-192 |
| 2647 | Brachytx, NS, Non-HDRIr-192 |
| 2648 | Brachytx planar, p-103 |
| 2698 | Brachytx, stranded, NOS |
| 2699 | Brachytx, non-stranded, NOS |
| 2731 | Immune globulin, powder |
| 2770 | Quinupristin/dalfopristin |
| 4001 | Echo guidance radiotherapy |
| 4002 | Stereoscopic x-ray guidance |
| 4003 | Radiation treatment delivery, MeV <= 5; simple |
| 4004 | Radiation treatment delivery, 6-10 MeV; simple |
| 4005 | Radiation treatment delivery, 11-19 MeV; simple |
| 4006 | Radiation treatment delivery, MeV>=20; simple |
| 4007 | Radiation treatment delivery, MeV<=5; intermediate |
| 4008 | Radiation treatment delivery, 6-10 MeV; intermediate |
| 4009 | Radiation treatment delivery, 11-19 MeV; intermediate |
| 4010 | Radiation treatment delivery, MeV >=20; intermediate |
| 4010 | Radiation treatment delivery, MeV >=20, Intermediate |
| 4012 | Radiation treatment delivery, 6-10 MeV; complex |
| 4012 | Radiation treatment delivery, 11-19 MeV; complex |
| 4013 | |
| 4014 | Radiation treatment delivery, MeV >=20; complex Radiation tx delivery imrt |
| 4016 | Delivery comp imrt |
| 5012 | Clinic Visits and Related Services |
| 5012 | Level 1 Type A ED Visits |
| 5021 | Level 2 Type A ED Visits |
| 5022 | Level 3 Type A ED Visits |
| 5023 | Level 4 Type A ED Visits |
| 5024 | Level 5 Type A ED Visits |
| 5025 | Level 1 Type B ED Visits |
| 5031 | Level 2 Type B ED Visits |
| 5032 | Level 3 Type B ED Visits |
| 5034 | Level 4 Type B ED Visits |
| 5035 | Level 5 Type B ED Visits |
| 5035 | Critical Care |
| 5045 | Trauma Response with Critical Care |
| 5045 5051 | Level 1 Skin Procedures |
| 5051 | Level 2 Skin Procedures |
| | |
| 5053 | Level 3 Skin Procedures |
| 5054 | Level 4 Skin Procedures |
| 5055 5061 | Level 5 Skin Procedures |
| 5061 | Hyperbaric Oxygen |
| 5071 | Level 1 Excision/ Biopsy/ Incision and Drainage |
| 5072 | Level 2 Excision/ Biopsy/ Incision and Drainage |
| 5073 | Level 3 Excision/ Biopsy/ Incision and Drainage |

| APC | Description |
|------|--|
| | Level 1 Breast/Lymphatic Surgery and Related |
| 5091 | Procedures |
| 5000 | Level 2 Breast/Lymphatic Surgery and Related |
| 5092 | Procedures Level 3 Breast/Lymphatic Surgery and Related |
| 5093 | Procedures |
| | Level 4 Breast/Lymphatic Surgery and Related |
| 5094 | Procedures |
| 5101 | Level 1 Strapping and Cast Application |
| 5102 | Level 2 Strapping and Cast Application |
| 5111 | Level 1 Musculoskeletal Procedures |
| 5112 | Level 2 Musculoskeletal Procedures |
| 5113 | Level 3 Musculoskeletal Procedures |
| 5114 | Level 4 Musculoskeletal Procedures |
| 5115 | Level 5 Musculoskeletal Procedures |
| 5116 | Level 6 Musculoskeletal Procedures |
| 5151 | Level 1 Airway Endoscopy |
| 5152 | Level 2 Airway Endoscopy |
| 5153 | Level 3 Airway Endoscopy |
| 5154 | Level 4 Airway Endoscopy |
| 5155 | Level 5 Airway Endoscopy |
| 5161 | Level 1 ENT Procedures |
| 5162 | Level 2 ENT Procedures |
| 5163 | Level 3 ENT Procedures |
| 5164 | Level 4 ENT Procedures |
| 5165 | Level 5 ENT Procedures |
| 5166 | Cochlear Implant Procedure |
| 5181 | Level 1 Vascular Procedures |
| 5182 | Level 2 Vascular Procedures |
| 5183 | Level 3 Vascular Procedures |
| 5184 | Level 4 Vascular Procedures |
| 5191 | Level 1 Endovascular Procedures |
| 5192 | Level 2 Endovascular Procedures |
| 5193 | Level 3 Endovascular Procedures |
| 5194 | Level 4 Endovascular Procedures |
| 5200 | Implantation Wireless PA Pressure Monitor |
| 5211 | Level 1 Electrophysiologic Procedures |
| 5212 | Level 2 Electrophysiologic Procedures |
| 5213 | Level 3 Electrophysiologic Procedures |
| 5221 | Level 1 Pacemaker and Similar Procedures |
| 5222 | Level 2 Pacemaker and Similar Procedures |
| 5223 | Level 3 Pacemaker and Similar Procedures |
| 5224 | Level 4 Pacemaker and Similar Procedures |
| 5231 | Level 1 ICD and Similar Procedures |
| 5232 | Level 2 ICD and Similar Procedures |
| 5241 | Level 1 Blood Product Exchange and Related Services |
| 5241 | Level 2 Blood Product Exchange and Related |
| 5242 | Services |
| 5243 | Level 3 Blood Product Exchange and Related Services |
| 5243 | 06101063 |

| APC 5244 5301 | Description Level 4 Blood Product Exchange and Related |
|----------------------------|--|
| | |
| 5301 | Services |
| 0001 | Level 1 Upper GI Procedures |
| 5302 | Level 2 Upper GI Procedures |
| 5303 | Level 3 Upper GI Procedures |
| 5311 | Level 1 Lower GI Procedures |
| 5312 | Level 2 Lower GI Procedures |
| 5313 | Level 3 Lower GI Procedures |
| 5331 | Complex GI Procedures |
| | Level 1 Abdominal/Peritoneal/Biliary and Related |
| 5341 | Procedures |
| 5342 | Level 2 Abdominal/Peritoneal/Biliary and Related Procedures |
| 5361 | |
| 5362 | Level 1 Laparoscopy and Related Services |
| | Level 2 Laparoscopy and Related Services |
| 5371 | Level 1 Urology and Related Services |
| 5372 | Level 2 Urology and Related Services |
| 5373 | Level 3 Urology and Related Services |
| 5374 | Level 4 Urology and Related Services |
| 5375 | Level 5 Urology and Related Services |
| 5376 | Level 6 Urology and Related Services |
| 5377 | Level 7 Urology and Related Services |
| 5378 | Level 8 Urology and Related Services |
| 5401 | Dialysis |
| 5411 | Level 1 Gynecologic Procedures |
| 5412 | Level 2 Gynecologic Procedures |
| 5413 | Level 3 Gynecologic Procedures |
| 5414 | Level 4 Gynecologic Procedures |
| 5415 | Level 5 Gynecologic Procedures |
| 5416 | Level 6 Gynecologic Procedures |
| 5431 | Level 1 Nerve Procedures |
| 5432 | Level 2 Nerve Procedures |
| 5441 | Level 1 Nerve Injections |
| 5442 | Level 2 Nerve Injections |
| 5443 | Level 3 Nerve Injections |
| 5461 | Level 1 Neurostimulator and Related Procedures |
| 5462 | Level 2 Neurostimulator and Related Procedures |
| 5463 | Level 3 Neurostimulator and Related Procedures |
| 5464 | Level 4 Neurostimulator and Related Procedures |
| 5465 | Level 5 Neurostimulator and Related Procedures |
| 5471 | Implantation of Drug Infusion Device |
| 5481 | Laser Eye Procedures |
| 5491 | Level 1 Intraocular Procedures |
| 5492 | Level 2 Intraocular Procedures |
| 5493 | Level 3 Intraocular Procedures |
| 5494 | Level 4 Intraocular Procedures |
| 5495 | Level 5 Intraocular Procedures |
| 5496 | Level 6 Intraocular Procedures |
| | Level 1 Extraocular, Repair, and Plastic Eye |
| 5501 | Procedures |

| APC | Description |
|--------------|--|
| | Level 2 Extraocular, Repair, and Plastic Eye |
| 5502 | Procedures |
| | Level 3 Extraocular, Repair, and Plastic Eye |
| 5503 | Procedures Level 4 Extraocular, Repair, and Plastic Eye |
| 5504 | Procedures |
| 5521 | Level 1 Imaging without Contrast |
| 5522 | Level 2 Imaging without Contrast |
| 5523 | Level 3 Imaging without Contrast |
| 5524 | Level 4 Imaging without Contrast |
| 5571 | Level 1 Imaging with Contrast |
| 5572 | Level 2 Imaging with Contrast |
| 5573 | Level 3 Imaging with Contrast |
| 5591 | Level 1 Nuclear Medicine and Related Services |
| 5592 | Level 2 Nuclear Medicine and Related Services |
| 5593 | Level 3 Nuclear Medicine and Related Services |
| 5594 | Level 4 Nuclear Medicine and Related Services |
| 5611 | Level 1 Therapeutic Radiation Treatment Preparation |
| 5612 | Level 2 Therapeutic Radiation Treatment Preparation |
| 5613 | Level 3 Therapeutic Radiation Treatment Preparation |
| 5621 | |
| | Level 1 Radiation Therapy |
| 5622 5623 | Level 2 Radiation Therapy Level 3 Radiation Therapy |
| | |
| 5624 | Level 4 Radiation Therapy |
| 5625 | Level 5 Radiation Therapy |
| 5626 | Level 6 Radiation Therapy |
| 5627 | Level 7 Radiation Therapy |
| 5661 | Therapeutic Nuclear Medicine |
| 5671 | Level 1 Pathology |
| 5672 | Level 2 Pathology |
| 5673 5674 | Level 3 Pathology |
| | Level 4 Pathology |
| 5691 | Level 1 Drug Administration |
| 5692 | Level 2 Drug Administration |
| 5693 | Level 3 Drug Administration |
| 5694 | Level 4 Drug Administration |
| 5721 | Level 1 Diagnostic Tests and Related Services |
| 5722 | Level 2 Diagnostic Tests and Related Services |
| 5723 | Level 3 Diagnostic Tests and Related Services |
| 5724 | Level 4 Diagnostic Tests and Related Services |
| 5731 | Level 1 Minor Procedures |
| 5732 | Level 2 Minor Procedures |
| 5733 | Level 3 Minor Procedures |
| 5734 | Level 4 Minor Procedures |
| 5735 | Level 5 Minor Procedures |
| 5741 | Level 1 Electronic Analysis of Devices |
| 5742 | Level 2 Electronic Analysis of Devices |
| 5743 | Level 3 Electronic Analysis of Devices |
| 5771 | Cardiac Rehabilitation |
| 5781 | Resuscitation and Cardioversion |
| 5791 | Pulmonary Treatment |

| APC | Description |
|------|---|
| 5801 | Ventilation Initiation and Management |
| 5811 | Manipulation Therapy |
| 5821 | Level 1 Health and Behavior Services |
| 5822 | Level 2 Health and Behavior Services |
| 5823 | Level 3 Health and Behavior Services |
| 5851 | Intensive Outpatient (3 services) for CMHCs |
| 5852 | Intensive Outpatient (4 or more services) for CMHCs |
| 5853 | Partial Hospitalization (3 services) for CMHCs |
| 0000 | Partial Hospitalization (4 or more services) for |
| 5854 | CMHCs |
| | Intensive Outpatient (3 services) for Hospital-based |
| 5861 | IOPs |
| 5862 | Intensive Outpatient (4 or more services) for Hospital- based IOPs |
| | Partial Hospitalization (3 services) for Hospital-based |
| 5863 | PHPs |
| 5004 | Partial Hospitalization (4 or more services) for |
| 5864 | Hospital-based PHPs |
| 5871 | Dental Procedures |
| 5881 | Ancillary Outpatient Services When Patient Dies |
| 7041 | Tirofiban hcl |
| 7043 | Infliximab not biosimil 10mg |
| 7046 | Doxorubicin inj 10mg |
| 7048 | Alteplase recombinant |
| 7308 | Aminolevulinic acid hcl top |
| 8004 | Ultrasound Composite |
| 8005 | CT and CTA without Contrast Composite |
| 8006 | CT and CTA with Contrast Composite |
| 8007 | MRI and MRA without Contrast Composite |
| 8008 | MRI and MRA with Contrast Composite |
| 8010 | Mental Health Services Composite |
| 8011 | Comprehensive Observation Services |
| 9002 | Tenecteplase injection |
| 9003 | Palivizumab |
| 9004 | Injection, inclisiran, 1 mg |
| 9005 | Reteplase injection |
| 9006 | Tacrolimus injection |
| 9007 | Inj cutaquig 100 mg |
| 9008 | Inj tezepelumab-ekko, 1mg |
| 9009 | Inj, vutrisiran, 1 mg |
| 9010 | Inj efgartigimod 2mg |
| 9011 | Mmrv vaccine sc |
| 9012 | Arsenic trioxide injection |
| 9013 | Inj risankizumab-rzaa?1 mg |
| 9016 | Inj., triptorelin xr 3.75 mg |
| 9017 | Inj. byooviz, 0.1 mg |
| 9018 | Inj, rimabotulinumtoxinB |
| 9020 | Argatroban nonesrd (accord) |
| 9021 | Argatroban dialysis (accord) |
| 9022 | Argatroban nonesrd (auromed) |
| 9023 | Argatroban dialysis, auromed |

Fee Schedule Guideline – Outpatient Hospital January 2024

| APC | Description |
|------|------------------------------|
| 9024 | Amphotericin b lipid complex |
| 9025 | Inj glucagon hcl, fresenius |
| 9026 | Inj, bortezomib, dr. reddy?s |
| 9027 | Inj, bortezomib freseniuskab |
| 9028 | Inj inotuzumab ozogam 0.1 mg |
| 9029 | Inj., guselkumab, 1 mg |
| 9030 | Inj., copanlisib, 1 mg |
| 9031 | Inj, etelcalcetide, 0.1 mg |
| 9032 | Baclofen 10 MG injection |
| 9033 | Cidofovir injection |
| 9034 | Inj cuvitru, 100 mg |
| 9035 | Axicabtagene ciloleucel car+ |
| 9036 | Injection, renflexis |
| 9037 | Aripiprazole injection |
| 9038 | Inj estrogen conjugate |
| 9039 | Dimecaprol injection |
| 9041 | Epoetin beta esrd use |
| 9042 | Glucagon hydrochloride |
| 9043 | Inj, afstyla, 1 i.u. |
| 9044 | Ibutilide fumarate injection |
| 9045 | Idursulfase injection |
| 9046 | Inj., fibryga, 1 mg |
| 9047 | Leuprolide acetate injeciton |
| 9048 | Inj, alymsys, 10 mg |
| 9049 | Inj, oliceridine 0.1 mg |
| 9050 | Leuprolide inj, camcevi, 1mg |
| 9051 | Inj, lanreotide, (cipla) 1mg |
| 9053 | Fluorodopa f-18 diag per mci |
| 9054 | Lutetium lu 177 vipivotide |
| 9055 | Gallium locametz 1 millicuri |
| 9057 | Inj nivol relatlimab 3mg/1mg |
| 9058 | Buprenorphine implant 74.2mg |
| 9059 | Vonvendi inj 1 iu vwf:rco |
| 9065 | Argatroban esrd dialysis 1mg |
| 9067 | Lutetium lu 177 dotatat ther |
| 9068 | Smallpox&monkeypox vac 0.5ml |
| 9069 | Phenobarbital sodium inj |
| 9070 | Inj luxturna 1 billion vec g |
| 9071 | Capsaicin 8% patch |
| 9073 | Buprenorph xr 100 mg or less |
| 9074 | Makena, 10 mg |
| 9075 | Inj, kovaltry, 1 i.u. |
| 9077 | Epoetin beta non esrd |
| 9078 | Testosterone undecanoate 1mg |
| 9079 | Genvisc 850, inj, 1mg |
| 9080 | Fludarabine phosphate inj |
| 9087 | Inj, clevidipine butyrate |
| 9088 | Peng benzathine/procaine inj |
| 9094 | Radiesse injection |

| APCDescription9095Inj, sculptra, 0.5mg9096Inj retacrit esrd on dialysi9097Inj retacrit non-esrd use9099Inj fosnetupitant, palonoset9100Inj, bortezomib, hospira9101Vaccinia vrs vac 0.3 ml perq9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit9105Inj pemetrexed (teva) 10mg | |
|--|--|
| 9096Inj retacrit esrd on dialysi9097Inj retacrit non-esrd use9099Inj fosnetupitant, palonoset9100Inj, bortezomib, hospira9101Vaccinia vrs vac 0.3 ml perq9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9097Inj retacrit non-esrd use9099Inj fosnetupitant, palonoset9100Inj, bortezomib, hospira9101Vaccinia vrs vac 0.3 ml perq9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9099Inj fosnetupitant, palonoset9100Inj, bortezomib, hospira9101Vaccinia vrs vac 0.3 ml perq9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9100Inj, bortezomib, hospira9101Vaccinia vrs vac 0.3 ml perq9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9101Vaccinia vrs vac 0.3 ml perq9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9102Inj, fulvestrant (teva)9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9103Inj, fulvestrant (fresenius)9104Antithymocyte globuln rabbit | |
| 9104 Antithymocyte globuln rabbit | |
| | |
| | |
| 9106 Inj, bupivacaine (posimir) | |
| 9107 Inj, aponvie, 1 mg | |
| 9108 Thyrotropin injection | |
| 9109 Inj, elahere, 1 mg | |
| 9110 Inj, tremelimumab-actl, 1 mg | |
| 9111 Inj teclistamab cqyv 0.5 mg | |
| 9112 Inj teplizumab mzwv 5 mcg | |
| 9113 Inj olipudase alfa-rpcp 1mg | |
| 9114 Inj eflapegrastim-xnst 0.1mg | |
| 9115 Inj, spesolimab-sbzo, 1 mg | |
| 9116 Chloroprocaine opht gel, 1mg | |
| 9117 Inj, cimerli, 0.1 mg | |
| 9118 Inj, fylnetra, 0.5 mg | |
| 9119 Inj sodium thiosulfate 100mg | |
| 9120 Injection, Fulvestrant | |
| 9122 Triptorelin pamoate | |
| 9123 Inj pemetrexed, hospira 10mg | |
| 9125 Risperidone, long acting | |
| 9126 Natalizumab injection | |
| 9127 Inj pemetrexed (accord) 10mg | |
| 9128 Inj pemetrexed (sandoz) 10mg | |
| 9129 Inj, stimufend, 0.5 mg | |
| 9130 Inj, Imm Glob Bivigam, 500mg | |
| 9131 Inj, Ado-trastuzumab Emt 1mg | |
| 9132 Prothrombin complex kcentra | |
| 9133 Rabies ig, im/sc | |
| 9134 Rabies ig, heat treated | |
| 9135 Varicella-zoster ig, im | |
| 9136 Leuprolide depot cipla 7.5mg | |
| 9138 Inj, hemgenix, per tx dose | |
| 9139 Rabies vaccine, im | |
| 9140 Rabies vaccine, id | |
| 9141 Inj onase abepar-xioi treat | |
| 9142 Fecal?microbiota jslm 1 ml | |
| 9143 Inj acetaminophen -fresenius | |
| 9144 Inj, panzyga, 500 mg | |
| 9145 Inj, invega hafyera/trinza | |
| 9146 Inj, ixinity, 1 i.u. | |
| 9149 Inj ublituximab-xiiy, 1 mg | |

| APC | Description |
|--------------|--|
| 9150 | Inj mosunetuzumab-axgb, 1 mg |
| 9151 | Inj apotex/bendamustine 1 mg |
| 9152 | Paclitaxel (american regent) |
| 9153 | Inj bendamustine, baxter 1mg |
| 9154 | Inj, bendamustine, 1 mg |
| 9155 | Inj, lenacapavir, 1 mg |
| 9156 | Inj pemetrexed ditromethamin |
| 9157 | Inj, lecanemab-irmb, 1 mg |
| 9158 | Inj, pegcetacoplan, 1mg |
| 9159 | Inj, vegzelma, 10 mg |
| 9160 | Inj, acetaminophen (b braun) |
| 9161 | Inj, acetaninophen (b bradit) |
| 9162 | Inj. cefepime hcl (baxter) |
| 9163 | Inj. cefepime hcl (b braun) |
| 9164 | |
| | Inj, daptomycin (hospira) |
| 9165 9166 | Inj, decitabine (sun pharma) |
| | Inj, fosaprepitant (teva) |
| 9167 | Inj, linezolid (hospira) |
| 9168 | Inj, meropenem (b. braun) |
| 9169 | Inj, micafungin (par pharm) |
| 9170 | Inj midazolam (wg crit care) |
| 9171 | Factor ix idelvion inj |
| 9173 | Injection, fulphila |
| 9174 | Inj, durolane 1 mg |
| 9178 | Inj., meropenem, vaborbactam |
| 9179 | Inj., aristada initio, 1 mg |
| 9180 9181 | Inj., patisiran, 0.1 mg |
| | Inj., perseris, 0.5 mg |
| 9182 | Inj mogamulizumab-kpkc, 1 mg |
| 9183 | Inj., plazomicin, 5 mg Inj., rituximab, 10 mg |
| 9186 | |
| 9187 9188 | Injection, burosumab-twza 1m |
| | Inj crotalidae im f(ab')2 eq Inj., ibalizumab-uiyk, 10 mg |
| 9189 9193 | Nivestym |
| | |
| 9194 | Tisagenlecleucel car-pos t |
| 9195 | Injection, udenyca 0.5 mg |
| 9196 9197 | Inj, trivisc 1 mg |
| | Inj., fremanezumab-vfrm 1 mg |
| 9198 | Inj andexxa, 10 mg |
| 9199 | Injection, caplacizumab-yhdp |
| 9200 | Inj, remdesivir, 1 mg |
| 9201 | Rabies ig ht/ human im/sc |
| 9202 | Difelikefalin, esrd on dialy |
| 9203 | Inj cyclophosphamd auromedic |
| 9204 | Inj tisotu vedotin-tftv, 1mg |
| 9205 | Inj lon tesirin-Ipyl 0.075mg |
| 9206 | Inj plasminogen tvmh 1mg |
| 9207 | Injection, bortezomib, 0.1mg |

| ADC | Description |
|------|------------------------------|
| APC | Description |
| 9208 | Agalsidase beta injection |
| 9209 | Laronidase injection |
| 9211 | Inj, morphine (fresenius) |
| 9212 | Inj moxifloxacin (fres kabi) |
| 9213 | Inj. pemetrexed nos 10mg |
| 9214 | Bevacizumab injection |
| 9215 | Cetuximab injection |
| 9216 | Inj, naloxone hcl (zimhi) |
| 9217 | Leuprolide acetate suspnsion |
| 9218 | Chloroprocaine hcl injection |
| 9219 | Procainamide hcl injection |
| 9220 | Inj. tigecycline (accord) |
| 9221 | Inj, vancomycin hcl (mylan) |
| 9222 | Inj, vancomycin hcl (xellia) |
| 9223 | Bladder calculi irrig sol |
| 9224 | Galsulfase injection |
| 9225 | Fluocinolone acetonide implt |
| 9226 | Calcium glucon (fresenius) |
| 9229 | Ibandronate sodium injection |
| 9230 | Abatacept injection |
| 9233 | Ranibizumab injection |
| 9234 | Alglucosidase alfa injection |
| 9235 | Panitumumab injection |
| 9236 | Eculizumab injection |
| 9237 | Inj, lanreotide acetate |
| 9238 | Calcium glucon (wg critical) |
| 9239 | Buprenorphine xr over 100 mg |
| 9240 | Injection, ixabepilone |
| 9241 | Inj sirolimus prot part 1 mg |
| 9243 | Inj., treanda 1 mg |
| 9244 | Inj gemcitabine hcl (accord) |
| 9245 | Romiplostim injection |
| 9246 | Inj, abilify asimtufii, 1 mg |
| 9247 | Inj, amisulpride, 1 mg |
| 9249 | Inj buprenorph (brixadi) 1mg |
| 9250 | Inj epcoritamab-bysp 0.16 mg |
| 9251 | C1 esterase inhibitor inj |
| 9252 | Plerixafor injection |
| 9253 | Temozolomide injection |
| 9254 | Flotufolastat f18 diag 1 mci |
| 9255 | Inj, invega sustenna, 1 mg |
| 9256 | Dexamethasone intra implant |
| 9257 | Inj., emicizumab-kxwh 0.5 mg |
| 9258 | Telavancin injection |
| 9259 | Pralatrexate injection |
| 9260 | Ofatumumab injection |
| 9261 | Ustekinumab sub cu inj, 1 mg |
| 9262 | Inj tofersen intrathec 1 mg |
| | |
| 9263 | Ecallantide injection |

| APC | Description |
|------|------------------------------|
| 9264 | Tocilizumab injection |
| 9266 | Inj, uzedy, 1 mg |
| 9267 | Inj, rezafungin, 1 mg |
| 9268 | Inj. acthar gel to 40 units |
| 9269 | C-1 esterase, berinert |
| 9270 | Gammaplex IVIG |
| 9271 | Velaglucerase alfa |
| 9272 | Inj, denosumab |
| 9273 | Sipuleucel-T auto CD54+ |
| 9274 | Crotalidae Poly Immune Fab |
| 9275 | Inj. (ani), up to 40 units |
| 9276 | Cabazitaxel injection |
| 9277 | Altuviiio per factor viii iu |
| 9278 | Incobotulinumtoxin A |
| 9279 | Inj. mycophenolate mofetil |
| 9280 | Inj, retifanlimab-dlwr, 1 mg |
| 9281 | Injection, pegloticase |
| 9282 | Inj, acetaminophen (hikma) |
| 9283 | Inj, epinephrine (belcher) |
| 9284 | Ipilimumab injection |
| 9285 | Inj allopurinol sodium 1 mg |
| 9286 | Belatacept injection |
| 9287 | Brentuximab vedotin inj |
| 9288 | Injection, aztreonam, 100 mg |
| 9289 | Erwinaze injection |
| 9290 | Inj, bupivacaine, nos, 0.5mg |
| 9291 | Inj, clindamycin phosp 300mg |
| 9292 | Inj, clindamycin (baxter) |
| 9294 | Inj, taliglucerase alfa 10 u |
| 9295 | Injection, Carfilzomib, 1 mg |
| 9296 | Inj, ziv-aflibercept, 1mg |
| 9297 | Inj, Omacetaxine Mep, 0.01mg |
| 9298 | Inj, Ocriplasmin, 0.125 mg |
| 9299 | Inj. jivi 1 iu |
| 9300 | Omalizumab injection |
| 9301 | Aminolevulinic acid, 10% gel |
| 9302 | Inj daunorubicin, cytarabine |
| 9304 | Inj., cemiplimab-rwlc, 1 mg |
| 9305 | Inj., lumoxiti, 0.01 mg |
| 9306 | Inj., tildrakizumab, 1 mg |
| 9309 | Inj. tagraxofusp-erzs 10 mcg |
| 9310 | Inj., emapalumab-Izsg, 1 mg |
| 9311 | Inj., omadacycline, 1 mg |
| 9312 | Inj., ravulizumab-cwvz 10 mg |
| 9313 | Inj. belrapzo/bendamustine |
| 9314 | Inj. herceptin hylecta, 10mg |
| 9318 | Inj hydroxyprogst capoat nos |
| 9319 | Somatropin injection |
| 9320 | Carbidopa levodopa ent 100ml |

| APC | Description |
|------|------------------------------|
| 9321 | Fosphenytoin inj pe |
| 9325 | Inj., eravacycline, 1 mg |
| 9327 | Inj. romosozumab-aqqg 1 mg |
| 9328 | Inj., yutiq, 0.01 mg |
| 9329 | Inj mvasi 10 mg |
| 9330 | Inj., kanjinti, 10 mg |
| 9331 | Inj, polatuzumab vedotin 1mg |
| 9332 | Inj lefamulin 1 mg |
| 9333 | Inj., brexanolone, 1 mg |
| 9334 | Injection, khapzory, 0.5 mg |
| 9336 | Inj truxima 10 mg |
| 9337 | Synojoynt, inj., 1 mg |
| 9338 | Inj., triluron, 1 mg |
| 9339 | lodine i-131 iobenguane 1mci |
| 9340 | Inj, brolucizumab-dbll, 1 mg |
| 9341 | Inj ogivri 10 mg |
| 9343 | Inj givosiran 0.5 mg |
| 9345 | Inj pegfilgrastim-bmez 0.5mg |
| 9346 | Mometasone sinus sinuva |
| 9347 | Inj luspatercept-aamt 0.25mg |
| 9348 | Inj., zirabev, 10 mg |
| 9349 | Inj herzuma 10 mg |
| 9350 | Inj., trazimera, 10 mg |
| 9351 | Inj bimatoprost itc imp 1mcg |
| 9352 | Chloroquine injection |
| 9353 | Inj fam-trastu deru-nxki 1mg |
| 9354 | Inj recombin esperoct per iu |
| 9355 | Inj. teprotumumab-trbw 10 mg |
| 9356 | Inj golodirsen 10 mg |
| 9357 | Inj. eptinezumab-jjmr 1 mg |
| 9358 | Inj xipere 1 mg |
| 9359 | Inj crizanlizumab-tmca 5mg |
| 9360 | Inj heparin, pfizer, 1000u |
| 9361 | Inj. cetirizine hcl 0.5mg |
| 9362 | Inj imip 4 cilas 4 releb 2mg |
| 9363 | Inj, esmolol hcl, 10mg |
| 9364 | Inj enfort vedo-ejfv 0.25mg |
| 9365 | Inj esmolol hcl wg crit care |
| 9366 | Fiasp for insulin pump use |
| 9367 | Inj ruxience, 10 mg |
| 9368 | Lyumjev for insulin pump use |
| 9369 | Inj, metronidazole, 10 mg |
| 9372 | Inj. xembify, 100 mg |
| 9374 | Mitomycin instillation |
| 9375 | Inj., evomela, 1 mg |
| 9376 | Sacituzumab govitecan-hziy |
| 9377 | Inj. isatuximab-irfc 10 mg |
| 9378 | Daratumumab, hyaluronidase |
| 9381 | Inj. avsola, 10 mg |

| APC | Description |
|------|---|
| 9382 | Inj ontruzant 10 mg |
| 9383 | Copper cu 64 dotatate diag |
| 9384 | Inj belantamab mafodot blmf |
| 9385 | Inj., tafasitamab-cxix |
| 9386 | Inj. viltolarsen |
| 9387 | Inj. infugem, 100 mg |
| 9388 | Inj. fe derisomaltose 10 mg |
| 9389 | _ |
| | Inj. lurbinectedin, 0.1 mg |
| 9390 | Pertuzu, trastuzu, 10 mg |
| 9391 | Brexucabtagene car pos t |
| 9392 | Inj. asceniv |
| 9393 | Inj codeine phosphate /30 mg |
| 9394 | Inj. inebilizumab-cdon, 1 mg |
| 9395 | Factor viia recomb sevenfact |
| 9396 | Afamelanotide implant, 1 mg |
| 9397 | Covid-19 Vaccine Admin Dose 1 of 2 |
| 9398 | Covid-19 Vaccine Admin Dose 2 of 2, Single Dose Product or Additional Dose |
| 3330 | Pneumococcal, Influenza, Hepatitis B, and/or Covid- |
| 9399 | 19 Vaccine Home Administration |
| 9400 | Inj, labetalol hcl, 5mg |
| 9401 | Bebtelovimab 175 mg |
| 9402 | Inj labetalol hcl hikma, 5mg |
| 9403 | Methylnaltrexone injection |
| 9404 | Inj, nitroglycerin, 5 mg |
| 9405 | Inj, biorphen, 20 micrograms |
| 9406 | Inj, nyvepria |
| 9407 | Inj. lumasiran, 0.5 mg |
| 9408 | Inj. naxitamab-gqgk, 1 mg |
| 9409 | Gallium ga-68 psma-11 ucsf |
| 9410 | Gallium ga-68 psma-11, ucla |
| 9411 | Inj. riabni, 10 mg |
| 9412 | Injection, casimersen, 10 mg |
| 9413 | lisocabtagene car pos t |
| 9414 | Inj, cabote rilpivir 2mg 3mg |
| 9415 | Injection, trilaciclib, 1mg |
| 9416 | Inj, evinacumab-dgnb, 5 mg |
| 9417 | Inj, melphalan flufenami 1mg |
| 9418 | Inj. margetuximab-cmkb, 5 mg |
| 9419 | Inj fensolvi 0.25 mg |
| 9420 | Eptifibatide injection |
| 9421 | Inj, granisetron, xr, 0.1 mg |
| 9422 | Idecabtagene vicleucel car |
| 9426 | Inj, cefiderocol, 10 mg |
| 9427 | Injection, oritavancin 10 mg |
| 9428 | Inj romidepsin non-lyo 0.1mg |
| 9429 | Inj romidepsin lyophil 0.1mg |
| 9430 | Piflu f-18, dia 1 millicurie |
| 9431 | Inj, dostarlimab-gxly, 10 mg |
| 9431 | Inj, adistanimab-galy, to mg |
| 0402 | ing, annvananao-vilijw |

| APC | Description |
|------|--|
| 9433 | Inj aval alfa-nqpt 4mg |
| | Inj avia alia-hypt 4hy Inj anifrolumab-fnia 1mg |
| 9434 | |
| 9436 | Inj pegfilgrast ex bio 0.5mg |
| 9437 | Inj, aspara, rylaze, 0.1 mg |
| 9438 | Injection, aducanumab-avwa, 2 mg |
| 9439 | Inj, susvimo 0.1 mg |
| 9440 | Instill, bupivac and meloxic |
| 9441 | Inj ferric carboxymaltos 1mg |
| 9442 | Inj. pemetrexed, 10 mg |
| 9443 | Gallium illuccix 1 millicure |
| 9444 | Inj, sutimlimab-jome, 10 mg |
| 9445 | Injection, ruconest |
| 9446 | Inj, tebentafusp-tebn, 1 mcg |
| 9447 | Inj, releuko 1 mcg |
| 9448 | Oral netupitant, palonosetro |
| 9449 | Injection, blinatumomab |
| 9450 | Fluocinol acet intravit imp |
| 9451 | Injection, peramivir |
| 9452 | Inj ceftolozane tazobactam |
| 9453 | Injection, nivolumab |
| 9454 | Inj, pasireotide long acting |
| 9455 | Injection, siltuximab |
| 9456 | Injection, isavuconazonium |
| 9460 | Injection, cangrelor |
| 9463 | Inj., aprepitant, 1 mg |
| 9466 | Inj., benralizumab, 1 mg |
| 9467 | Inj rituximab, hyaluronidase |
| 9468 | Factor ix recomb gly rebinyn |
| 9469 | Inj triamcinolone ace xr 1mg |
| 9470 | Aripirazole lauroxil 1 mg |
| 9471 | Hymovis injection 1 mg |
| 9472 | Inj talimogene laherparepvec |
| 9473 | Injection, mepolizumab, 1mg |
| 9474 | Inj irinotecan liposome 1 mg |
| 9475 | Injection, necitumumab, 1 mg |
| 9476 | Injection, daratumumab 10 mg |
| 9477 | Injection, elotuzumab, 1mg |
| 9478 | Inj sebelipase alfa 1 mg |
| 9479 | Ciprofloxacin otic susp 6 mg |
| 9480 | Injection trabectedin 0.1mg |
| 9481 | Injection realizumab |
| 9482 | Sotalol hydrochloride IV |
| 9483 | Inj, atezolizumab,10 mg |
| 9487 | Ustekinumab, iv inject,1 mg |
| 9488 | Conivaptan hcl |
| | |
| 9489 | Inj, nusinersen, 0.1mg |
| 9490 | Inj, bezlotoxumab, 10 mg |
| 9491 | Injection, avelumab, 10 mg |
| 9492 | Inj., durvalumab, 10 mg |

| APC | Description |
|------|------------------------------|
| 9493 | Injection, edaravone, 1 mg |
| 9494 | Injection, ocrelizumab |
| 9495 | Gemtuzumab ozogamicin inj |
| 9496 | Inj, faricimab-svoa, 0.1mg |
| 9498 | Ciltacabtagene car-pos t |
| 9499 | Adenovirus vaccine type 4 |
| 9500 | Platelets, irradiated |
| 9501 | Platelet pheres leukoreduced |
| 9502 | Platelet pheresis irradiated |
| 9503 | Fr frz plasma donor retested |
| 9504 | RBC deglycerolized |
| 9505 | RBC irradiated |
| 9507 | Platelets, pheresis |
| 9508 | Plasma 1 donor frz w/in 8 hr |
| 9509 | Frozen plasma, pooled, sd |
| 9510 | Whole blood for transfusion |
| 9511 | Cryoprecipitate each unit |
| 9512 | RBC leukocytes reduced |
| 9513 | Plasma, frz between 8-24hour |
| 9514 | Plasma protein fract,5%,50ml |
| 9515 | Platelets, each unit |
| 9516 | Plaelet rich plasma unit |
| 9517 | Red blood cells unit |
| 9518 | Washed red blood cells unit |
| 9519 | Plasmaprotein fract,5%,250ml |
| 9520 | Blood split unit |
| 9521 | Platelets leukoreduced irrad |
| 9522 | RBC leukoreduced irradiated |
| 9523 | Cryoprecipitatereducedplasma |
| 9524 | Blood, I/r, cmv-neg |
| 9525 | Platelets, hla-m, l/r, unit |
| 9526 | Platelets leukocytes reduced |
| 9527 | Blood, I/r, froz/degly/wash |
| 9528 | Plt, aph/pher, l/r, cmv-neg |
| 9529 | Blood, I/r, irradiated |
| 9530 | Plate pheres leukoredu irrad |
| 9531 | Plt, pher, I/r cmv-neg, irr |
| 9532 | RBC, frz/deg/wsh, l/r, irrad |
| 9533 | RBC, I/r, cmv-neg, irrad |
| 9534 | Pathogen reduced plasma pool |
| 9535 | Pathogen reduced plasma sing |
| 9536 | Platelets pheresis path redu |
| 9537 | Blood component/product noc |
| 9538 | Plasma cryo redu path each |
| 9539 | Cryo fib comp path redu each |
| 9540 | Covid-19 convalescent plasma |

North Dakota Workforce Safety & Insurance Outpatient Hospital APC Grouper Returns

| Return | Description |
|--------|--|
| 19900 | Incidental services packaged into APC rate |
| 19901 | Clinical diagnostic laboratory services |
| 19902 | Physical, occupational and speech-related services |
| 19903 | Ambulance Service |
| 19904 | Durable medical equipment, prosthetics, orthotics and supplies |
| 19905 | ERSD related drugs |
| 19906 | Physician service for ERSD |
| 19907 | Screening Mammography |
| 19908 | Diabetic Education |
| 19909 | Pulmonary rehabilitation clinical trial |
| 19911 | Diagnostic mammography |
| 19914 | Prenatal care |
| 19915 | Electrocardiogram report |
| 19916 | Medical Nutrition |
| 19917 | Ultrasound Bone stimulation |
| 19918 | Cochlear implant services |
| 19919 | Orphan drugs |
| 19920 | Activity therapy for partial hospitalization |
| 19921 | Occupational therapy for partial hospitalization |
| 19922 | Partial hospital program services |
| 19923 | Miscellaneous physician services |
| 19924 | CRNA anesthetist services |
| 19925 | Corneal tissue pass through |
| 19926 | Telehealth Services |
| 19927 | Flu/PPV vaccine |
| 19928 | Flu/PPV vaccine administration |
| 19929 | Neuromodulation Services |
| 19930 | Self-Administration Drugs |

| Return | Description |
|--------|--|
| 19932 | Miscellaneous Non-Opps Services |
| 19933 | Demonstration Project |
| 19934 | Other vaccines not payable under OPPS |
| 19935 | New procedure code - not included in |
| | grouping or editing - pending for review |
| 19936 | Conditionally packaged service - item |
| | packaged into APC rate |
| 19937 | Packaged service included in Composite |
| | APC rate |
| 19944 | Implanted prosthetic device for Part B |
| | hospital inpatient |
| 19945 | Chronic Kidney disease educational |
| | services |
| 19946 | Preventive medicine services |
| 19947 | Non Payable functional therapy code |
| 19948 | Separately payable clinical diagnostic |
| | laboratory services |
| 19949 | Packaged clinical diagnostic laboratory |
| | services |
| 19950 | Packaged Service included in |
| | Comprehensive APC rate |
| 19990 | Invalid procedure code |
| 19991 | Inpatient procedure |
| 19992 | Medicare non-covered item or service |
| 19993 | Non-Allowed item or service for OPPS |
| 19994 | must bill code to DMERC |
| 19995 | Service no billable to the MAC |
| 19996 | Payment status not determined - criteria |
| | not met for payment or packaging |
| 19997 | Medicare non-covered, no payment info |
| | available |



1600 E Century Ave, Suite 1 PO Box 5585 Bismarck, ND 58506-5585 701-328-3800 800-777-5033 Fax: 701-328-3820

www.workforcesafety.com